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Cell fusion: A hidden enemy?
The recent findings that cell fusion may be involved in stem cell
differentiation (Medvinsky and Smith, 2003) raise a possibility
that cell fusion has undiscovered functions, some of which can
perhaps be found by revisiting the old ideas that cell fusion can
promote disease, especially cancer.
Cell fusion is a process in which two or more cells become
one by merging their plasma membranes. The ability of a cell to
fuse to other cells is referred to as fusogenicity. The progeny of
cell fusion are known as hybrids. Perhaps the best-known
hybrids are hybridomas, which are made by fusing myeloma
cells with lymphocytes to produce monoclonal antibodies.
Although cells can be easily fused in the laboratory using readi-
ly available chemicals, cell fusion in live organisms appears to
be a complex, poorly understood, multistep process that
involves cell-cell recognition, cell adhesion, and membrane
fusion (reviewed in Hernandez et al., 1996).
Cell fusion is a part of normal development and tissue
homeostasis
Our life begins with fusion of our parents’ gametes. A pregnancy
depends on normal functioning of the placental barrier, the main
part of which is the syncytiotrophoblast, a gigantic syncytium (a
cell resulting from fusion of numerous cells) whose surface area
can reach 10 square meters (reviewed in Benirschke, 1998). As
the embryo develops, its muscles are formed by fusion of
myoblasts into syncytia through a multistep process that
involves products of multiple genes (reviewed in Taylor, 2002).
In the adult body, the maintenance of the bones is controlled in
part by osteoclasts, which are multinuclear cells formed by the
fusion of mononuclear progenitors. Macroscopic foreign
objects, such as a splinter or an implanted device, are encapsu-
lated by foreign body giant cells (FBGC) that attempt to dissolve
the intruder and are thought to be formed by fusion of mononu-
clear precursors (reviewed in Anderson, 2000). Langhans cells,
a variation of FBGC, are found in tuberculosis patients at the
sites of local inflammation.
The observations that embryonic stem cells may differenti-
ate into multiple cell types through cell fusion suggested a new
role of cell fusion in mammalian development (Terada et al.,
2002; Vassilopoulos et al., 2003; Wang et al., 2003; Ying et al.,
2002), although alternative explanations for these observations
have not been ruled out (McKay, 2002). Studies in the nema-
tode C. elegans (reviewed in Shemer and Podbilewicz, 2000;
Mohler et al., 2002) provide evidence that cell fusion can be a
major part of development, at least in invertebrates. About one-
third of the cells that are born in this organism are subsequently
fused into 44 syncytia in a reproducible and stereotypic way.
Remarkably, even the side of a cell that will fuse is predeter-
mined.
In summary, cell fusion of normal somatic cells is a tightly
controlled process that is restricted to only a few cell types in
humans, and results in terminally differentiated multinuclear
cells incapable of proliferation. Intriguingly, tumor cells appear
to violate strict rules of cell fusion.
Cell fusion and cancer
The idea that cell fusion contributes to cancer progression was
introduced almost 100 years ago with a proposal that malignan-
cy is a consequence of hybridization between leukocytes and
somatic cells (reviewed in Rachkovsky et al., 1998). Sixty years
later, this idea was expanded by proposing that hybridization of
tumor cells with lymphocytes results in metastatic cells (Mekler,
1971), and that cell fusion promotes the phenotypic and geno-
typic diversity of tumors (Warner, 1975). Several lines of evi-
dence support at least some of these notions.
Many tumor cells are fusogenic
The propensity of various tumor cells to fuse spontaneously in
tissue culture has been a known, though unexplained, phenom-
enon for many decades. In fact, this property of tumor cells was
used to make somatic cell hybrids before fusion with polyethyl-
ene glycol (PEG) or viruses had been developed (Barski and
Cornefert, 1962). Some tumor cell lines are so fusogenic that
they fuse spontaneously more efficiently than in the presence of
PEG, a difference explainable by the toxicity of this agent
(Wakeling et al., 1994). The ability to fuse is not limited to a par-
ticular cell or tumor type and can occur between tumor cells as
well as between a tumor and a normal cell (reviewed in Larizza
and Schirrmacher, 1984). Tumor cell fusion is not limited to tis-
sue culture. Human tumor cells injected into hamsters produced
metastases formed by hybrids of human and hamster cells
(Goldenberg et al., 1974). In another study, treatment of
chimeric mice with a carcinogen resulted in tumors, in which
about 1% of cells had marker alleles from both parental strains,
an observation explainable by cell fusion (Fortuna et al., 1990).
Interestingly, despite these observations, cell fusion is rarely, if
at all, considered in contemporary studies that use experimen-
tal models of cancer.
Because the evidence for cell fusion in human cancers is
indirect, it is not as compelling as that for experimental tumors.
One observation is that premature chromosome condensation
(PCC) is observed in tumor cells (Atkin, 1979; Kovacs, 1985;
Williams et al., 1976). PCC is a typical result of a fusion
between cells in different stages of the cell cycle, although PCC
can be also induced in mononuclear cells, for example by caf-
feine. Cell fusion could also explain the origin of multinuclear
tumor cells in which nuclei undergo asynchronous DNA synthe-
sis or mitosis, even though alternative explanations of this phe-
nomenon are as plausible (Sheehy et al., 1974). It is unclear
whether the scarcity of reports on cell fusion in human tumors is
due to rarity of this event, to a difficulty to detect it, or to insuffi-
cient interest in this subject. The last possibility should not be
underestimated. For example, the number of reports on apopto-
sis that were published during the last ten years is about 100
times higher than that published in the preceding twenty.With all
likelihood, this difference is due to a change in the subject’s
popularity rather than a change in incidence or role of apoptosis
in studied organisms.
Hybrids can be more malignant than the parental cells
Importantly, while physiological fusion of normal somatic cells
produces nonproliferating differentiated multinuclear cells,
fusion of tumor cells results in proliferating hybrids. The survival
rate of these hybrids in tissue culture can be as high as 1%
(Miller et al., 1988; Wakeling et al., 1994). Considering that the
rate of cell fusion in experimental tumors was also estimated at
1% (Fortuna et al., 1989), a 1 cm3 tumor of about 109 cells may
harbor 105 proliferating hybrid cells. The question is, can any of
these cells be more malignant than their parents?
In fact, one of the early reports on spontaneous cell fusion
came from an observation that cultures containing a mixture of
two mouse cell lines were occasionally overgrown by a new cell
line, whose karyotype was the sum of the parental karyotypes
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(Barski and Cornefert, 1962). This observation indicated that
the new cell line is a hybrid, and that hybrids can grow faster
than their parents. The subsequent studies indicated that, at
least in experimental systems, hybrids can be more drug-resis-
tant and more metastatic than the parental cells (Figure 1).
Cell fusion can contribute to drug resistance
Cell fusion can consolidate resistance to various drugs by com-
bining genes responsible for resistance to various agents. For
example, fusion of tumor cells that were resistant to 5-fluo-
rouracil with tumor cells resistant to methotrexate produced
hybrids that were resistant to both drugs (Miller et al., 1989). An
unexpected observation was that the hybrids were resistant to
mephalan, a drug to which both parental lines were sensitive.
This observation emphasized the difficulty in predicting the
diversity that cell fusion can create. Our own experiments indi-
cated that fusion of drug-sensitive transformed cells to primary
cells results in heterokaryons that are resistant to apoptosis
(Duelli and Lazebnik, 2000). Although this effect lasted only a
few days (our unpublished data), it is not unreasonable to spec-
ulate that even a temporary resistance may allow a small frac-
tion of tumor cells to survive a session of chemotherapy.
Cell fusion can promote the ability to metastasize
The ability to metastasize is, arguably, the deadliest property of
cancers. A proposed link between cell fusion and metastasis
can be described as the “wolf in sheep’s clothing” model. The
model suggests that a tumor cell becomes metastatic by fusion
to normal cells that travel throughout the body freely, such as
lymphocytes or macrophages. Several studies support this idea
(reviewed in Pawelek, 2000; Rachkovsky et al., 1998). One
study found that a parental cell line, when injected in a mouse,
produced hundreds of colonies in the liver, while a derivative
line produced only a few (Kerbel et al., 1983). Surprisingly, when
a colony formed by the derivative line was injected into a new
host, it produced as many colonies as did the parental cell line.
The analysis of histocompatibility markers and karyotypes of
the host mice, the injected cells, and the resulting metastases
led to the conclusion that the increase in the metastatic poten-
tial was due to a fusion with the host cells. This conclusion was
supported by the finding that the high metastatic potential can
be restored in the derivative cells by fusing them with mouse
bone marrow cells before injection.
Other studies discovered that cell fusion can determine the
tissues into which tumor cells metastasize. For example, fusion
of nonmetastatic mouse plasmacytoma
or myeloma cells with lymphocytes or
splenic dendritic cells not only resulted in
metastatic hybrids, but the target tissues
of metastases varied with the type of nor-
mal cells used as well (De Baetselier et
al., 1984). One can only wonder whether
implications of this finding are considered in developing cancer
vaccines, which involves injecting patients with hybrids between
tumor cells and normal dendritic cells. Because tissues that are
common sites of metastases are normally rich in macrophages,
the “wolf in sheep’s clothing” model argues that tumor cells
gravitate to these sites because, as macrophage hybrids, they
acquire macrophage’s tropism (Munzarova and Kovarik, 1987).
Another possibility is that tumor cells can acquire the
“sheep’s clothing” by fusing to a normal cell of a tissue, thus pro-
ducing a tumor cell that can grow in the new environment. This
mechanism is not unlike that proposed for the stem cell differen-
tiation, where a stem cell differentiates by fusing to a resident
cell from a host tissue (Medvinsky and Smith, 2003).
Cell fusion can increase tumor cell diversity
Perhaps the main property of cancer cells that makes them
malignant is the ability to produce diverse progeny. Indeed, as
an oncology textbook states, “…by the time of initial diagnosis,
cancers consist of multiple subpopulations of cells with diverse
genetic, biochemical, immunologic, and biologic characteris-
tics” (Fidler, 1997). How this diversity emerges and how it is
maintained is not clear. The evidence that cell fusion can con-
tribute to tumor heterogeneity came from using cell fusion as a
tool for somatic cell genetics, in particular to investigate whether
malignancy is a dominant or recessive trait. Because hybrids
between a highly and a weakly malignant tumor cell line were
highly malignant, the initial conclusion was that malignancy is a
dominant trait (Barski and Cornefert, 1962). However, the sub-
sequent studies found that hybrids between tumor cells and
normal cells were not tumorigenic (Harris, 1971; Stanbridge,
1976). The controversy was resolved by realizing that hybrids
become tumorigenic if they lose certain “normal” chromosomes,
an observation that eventually led to the discovery of tumor sup-
pressor genes (the history of the search is reviewed in
Anderson and Stanbridge, 1993; Harris, 1993).
A less appreciated outcome of these studies was the con-
clusion that chromosomal aberrations are hallmarks of hybrids.
These aberrations include chromosome nondisjunction, mitotic
recombination, translocations, deletions, insertions, and inver-
sions, a list that is remarkably similar to that observed in tumor
cells (reviewed in Larizza and Schirrmacher, 1984). Although
how exactly cell fusion causes these abnormalities is not clear,
the result is hardly surprising considering that cell fusion pro-
duces cells with a sum of parental chromosomes and more than
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Figure 1. Promiscuous cell fusion as a generator
of cell diversiy.
Physiological fusion of normal cells in the body is
tightly controlled. However, cellular or viral
fusion proteins, as well as environmental factors,
may induce cell fusion of bot tumor and normal
cells. Although the majority of the resulting cells
will die or be quiescent, a small fraction will be
able to proliferate. Some of the proliferating
cells may have unwanted properties, such as
increased malignancy.
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two centrosomes.
The aberrant chromosome segregation associated with cell
fusion was proposed to explain aneuploidy as a hallmark of
cancer cells. Although aneuplody is a feature of nearly all of
more than 20,000 solid tumors analyzed in humans (Heim and
Mitelman, 1995; Mertens et al., 1997), and it was even pro-
posed to be a cause rather than a consequence of cancer
(reviewed in Duesberg and Rasnick, 2000), how and why tumor
cells become aneuploid is not clear. The observation that tumor
cells are prone to cell fusion, the fact that fusion results in poly-
ploid cells, and the finding that cell fusion is followed by abnor-
mal chromosome segregation, together argue that if cell fusion
is a part of cancer progression, then tumor cells should eventu-
ally become aneuploid. However, this explanation of aneuploidy
by no means excludes other mechanisms, such as mutations
that cause abnormal mitosis.
Changes in epigenetic regulation that follow cell fusion are
another factor that can contribute to tumor diversity (reviewed in
Kikyo and Wolffe, 2000).These changes appear to be unpre-
dictable, and gene expression can be selectively silenced, acti-
vated, or unchanged (Ringertz and Savage, 1976). Considering
that the human body has about 200 cell types that are different
because of their gene expression pattern, it is easy to imagine
how cell fusion can produce monsters.
In summary, cell fusion can be an engine of genomic and
epigenetic variability that has a potential to make cells with new
properties at a rate exceeding that achievable by random muta-
genesis.
Why are tumor cells fusogenic?
There is no definitive answer to this question, which is not sur-
prising considering that the phenomenon lost whatever popular-
ity it had before modern experimental approaches capable of
dissecting its mechanism were developed. Several factors were
proposed to explain formation of hybrids in tumors: viruses (De
Baetselier et al., 1984), cholesterol crystals (Kerschmann et al.,
1995), and the natural fusogenicity of macrophages
(Munzarova and Kovarik, 1987).
The ability of viruses to induce cell fusion is mediated by the
viral proteins that mediate entry of enveloped viruses into the
cell. These proteins are members of the fusion protein family,
which includes both viral and cellular proteins (reviewed in
Martin and Ruysschaert, 2000). The fusion proteins are identi-
fied by a hydrophobic motif, known as the fusion peptide, which
is required for the fusogenicity of these proteins.
Perhaps any fusion protein or any other agent that induces
cell fusion should be investigated for its carcinogenicity. For
example, HIV is known to induce syncytia, which suggests that
in addition to its known role in disease (Fais et al., 1997;
Orenstein, 2001), it might be useful to investigate whether this
ability contributes to malignancies associated with this virus,
such as Kaposi’s sarcoma.
Remarkably, the genes that encode human endogenous
retroviruses (HERV) or their individual proteins, including the
fusion proteins, comprise at least eight percent of the human
genome (Griffiths, 2001). In fact, syncytin, the fusion protein
that is thought to mediate formation of the syncytiotrophoblast
and is specifically expressed in placenta, is the envelope fusion
protein of HERV-W (Mi et al., 2000). This finding indicates that
expression of HERV proteins can determine cell fate, and, inci-
dentally, gives support to the hypothesis that placental mam-
mals evolved because our ancestor had the germ line infected
with a retrovirus (Harris, 1998).
The sheer abundance of HERV genes in the human
genome provides an ample opportunity for their deregulated
expression. Indeed, HERV particles were found in both normal
and tumor tissues (Bieda et al., 2001). Production of HERV has
been associated with multiple sclerosis (Blond et al., 1999) and
cancer, although whether this association is causative is
unclear, in part because HERV particles do not appear to be
infectious. Perhaps a causal link between HERVs and these dis-
eases can be found by investigating whether these particles
induce cell fusion. Cell death is a predominant outcome of cell
fusion, which might explain how expression of HERV can lead
to multiple sclerosis, while the ability of some cells to survive
cell fusion can contribute to cancer, as we discussed.
Overall, at least in experimental systems, cell fusion has
been linked to several fundamental features of cancer, even
though molecular mechanisms that cause this fusion remain
obscure. Although one can argue that this link is a peculiarity of
experimental tumors, the hypothesis that cell fusion contributes
to cancer in humans seems to be equally plausible. Considering
that modern tools of experimental biology have not been
applied to studies of cell fusion in tumors, there is an abun-
dance of possibilities that are ready to be explored.
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